Kim M. Strohmaier

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 686 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

David A. Cooper, Roy T. Steigbigel, José M. Gatell et al. · New England Journal of Medicine · 2008 · 507 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +14

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

Robert F. Betts, Márcio Nucci, Deepak Talwar et al. · Clinical Infectious Diseases · 2009 · 213 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Roy T. Steigbigel, David A. Cooper, Hedy Teppler et al. · Clinical Infectious Diseases · 2010 · 205 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

The efficacy and safety of the Dorzolamide—timolol combination versus the concomitant administration of its components11Ms. Strohmaier and Drs. Snyder and Adamsons are employees of Merck & Co., Inc, the manufacturer of the dorzolamide-timolol combination. Dr. DuBiner has no proprietary interest in the dorzolamide-timolol combination or Merck.

Kim M. Strohmaier, Ellen Snyder, Harvey Dubiner et al. · Ophthalmology · 1998 · 139 citations

Pharmacy, Pharmacology, Pharmacotherapy +5